SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma

K. H. Chow, Pierce; Gandhi, Mihir; Tan, Say‐Beng; Win Khin, Maung; Khasbazar, Ariunaa; P. Ong, Janus; Pin Choo, Su; Chung Cheow, Peng; Chotipanich, Chanisa; Lim, Kieron; A. Lesmana, Laurentius; Wibawa Manuaba, Tjakra; Koon Yoong, Boon; Raj, Aloysius; Soon Law, Chiong; H.Y., Ian; Rey Lobo, Rolley; Teh, Catherine; Hwan Kim, Yun; Won Jong, Yun; Han, Ho‐Seong; Hyun Bae, Si; Yoon, Hyun‐Ki; Lee, Rheun‐Chuan; Hung, Chien‐Fu; Peng, Cheng‐Yuan; Liang, Po‐Chin; Bartlett, Adam; Yuh Yen Kok, Kenneth; Hua Thng, Choon; Low, Albert; Soon Whatt Goh, Anthony; Hiong Tay, Kiang; Lo, Richard; K. P. Goh, Brian; Chee Eng Ng, David; Lekurwale, Ganesh; Ming Liew, Wei; Gebski, Val; Mak, Kenneth; Chee Soo, Khee; behalf of Asia-Pacific Hepatocellular Carcinoma Trials Group, on

doi:10.1200/jco.2017.76.0892

Public

SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma

Published in Journal of Clinical Oncology • Mar 2, 2018

Authors:

Pierce K. H. Chow

Mihir Gandhi

Say‐Beng Tan

Abstract

Purpose Selective internal radiation therapy or radioembolization (RE) shows efficacy in unresectable hepatocellular carcinoma (HCC) limited to the liver. This study compared the safety and efficacy of RE and sorafenib in patients with locally advanced HCC. Patients and Methods SIRveNIB (selective i...

Subject

Sorafenib

Medicine

Hepatocellular carcinoma

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!